Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?

<p>Abstract</p> <p>Background</p> <p>Biochemical testing for pheochromocytoma by measurement of fractionated plasma metanephrines is limited by false positive rates of up to 18% in people without known genetic predisposition to the disease. The plasma normetanephrine fr...

Full description

Bibliographic Details
Main Authors: Gafni Amiram, Thabane Lehana, Sawka Anna M, Levine Mitchell, Young William F
Format: Article
Language:English
Published: BMC 2005-02-01
Series:BMC Endocrine Disorders
Online Access:http://www.biomedcentral.com/1472-6823/5/1
id doaj-01f064cb2f424ec3bab268fbbca637f5
record_format Article
spelling doaj-01f064cb2f424ec3bab268fbbca637f52020-11-25T03:24:50ZengBMCBMC Endocrine Disorders1472-68232005-02-0151110.1186/1472-6823-5-1Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?Gafni AmiramThabane LehanaSawka Anna MLevine MitchellYoung William F<p>Abstract</p> <p>Background</p> <p>Biochemical testing for pheochromocytoma by measurement of fractionated plasma metanephrines is limited by false positive rates of up to 18% in people without known genetic predisposition to the disease. The plasma normetanephrine fraction is responsible for most false positives and plasma normetanephrine increases with age. The objective of this study was to determine if we could improve the specificity of fractionated plasma measurements, by statistically adjusting for age.</p> <p>Methods</p> <p>An age-adjusted metanephrine score was derived using logistic regression from 343 subjects (including 33 people with pheochromocytoma) who underwent fractionated plasma metanephrine measurements as part of investigations for suspected pheochromocytoma at Mayo Clinic Rochester (derivation set). The performance of the age-adjusted score was validated in a dataset of 158 subjects (including patients 23 with pheochromocytoma) that underwent measurements of fractionated plasma metanephrines at Mayo Clinic the following year (validation dataset). None of the participants in the validation dataset had known genetic predisposition to pheochromocytoma.</p> <p>Results</p> <p>The sensitivity of the age-adjusted metanephrine score was the same as that of traditional interpretation of fractionated plasma metanephrine measurements, yielding a sensitivity of 100% (23/23, 95% confidence interval [CI] 85.7%, 100%). However, the false positive rate with traditional interpretation of fractionated plasma metanephrine measurements was 16.3% (22/135, 95% CI, 11.0%, 23.4%) and that of the age-adjusted score was significantly lower at 3.0% (4/135, 95% CI, 1.2%, 7.4%) (p < 0.001 using McNemar's test).</p> <p>Conclusion</p> <p>An adjustment for age in the interpretation of results of fractionated plasma metanephrines may significantly decrease false positives when using this test to exclude sporadic pheochromocytoma. Such improvements in false positive rate may result in savings of expenditures related to confirmatory imaging.</p> http://www.biomedcentral.com/1472-6823/5/1
collection DOAJ
language English
format Article
sources DOAJ
author Gafni Amiram
Thabane Lehana
Sawka Anna M
Levine Mitchell
Young William F
spellingShingle Gafni Amiram
Thabane Lehana
Sawka Anna M
Levine Mitchell
Young William F
Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?
BMC Endocrine Disorders
author_facet Gafni Amiram
Thabane Lehana
Sawka Anna M
Levine Mitchell
Young William F
author_sort Gafni Amiram
title Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?
title_short Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?
title_full Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?
title_fullStr Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?
title_full_unstemmed Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?
title_sort measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: can specificity be improved by adjustment for age?
publisher BMC
series BMC Endocrine Disorders
issn 1472-6823
publishDate 2005-02-01
description <p>Abstract</p> <p>Background</p> <p>Biochemical testing for pheochromocytoma by measurement of fractionated plasma metanephrines is limited by false positive rates of up to 18% in people without known genetic predisposition to the disease. The plasma normetanephrine fraction is responsible for most false positives and plasma normetanephrine increases with age. The objective of this study was to determine if we could improve the specificity of fractionated plasma measurements, by statistically adjusting for age.</p> <p>Methods</p> <p>An age-adjusted metanephrine score was derived using logistic regression from 343 subjects (including 33 people with pheochromocytoma) who underwent fractionated plasma metanephrine measurements as part of investigations for suspected pheochromocytoma at Mayo Clinic Rochester (derivation set). The performance of the age-adjusted score was validated in a dataset of 158 subjects (including patients 23 with pheochromocytoma) that underwent measurements of fractionated plasma metanephrines at Mayo Clinic the following year (validation dataset). None of the participants in the validation dataset had known genetic predisposition to pheochromocytoma.</p> <p>Results</p> <p>The sensitivity of the age-adjusted metanephrine score was the same as that of traditional interpretation of fractionated plasma metanephrine measurements, yielding a sensitivity of 100% (23/23, 95% confidence interval [CI] 85.7%, 100%). However, the false positive rate with traditional interpretation of fractionated plasma metanephrine measurements was 16.3% (22/135, 95% CI, 11.0%, 23.4%) and that of the age-adjusted score was significantly lower at 3.0% (4/135, 95% CI, 1.2%, 7.4%) (p < 0.001 using McNemar's test).</p> <p>Conclusion</p> <p>An adjustment for age in the interpretation of results of fractionated plasma metanephrines may significantly decrease false positives when using this test to exclude sporadic pheochromocytoma. Such improvements in false positive rate may result in savings of expenditures related to confirmatory imaging.</p>
url http://www.biomedcentral.com/1472-6823/5/1
work_keys_str_mv AT gafniamiram measurementoffractionatedplasmametanephrinesforexclusionofpheochromocytomacanspecificitybeimprovedbyadjustmentforage
AT thabanelehana measurementoffractionatedplasmametanephrinesforexclusionofpheochromocytomacanspecificitybeimprovedbyadjustmentforage
AT sawkaannam measurementoffractionatedplasmametanephrinesforexclusionofpheochromocytomacanspecificitybeimprovedbyadjustmentforage
AT levinemitchell measurementoffractionatedplasmametanephrinesforexclusionofpheochromocytomacanspecificitybeimprovedbyadjustmentforage
AT youngwilliamf measurementoffractionatedplasmametanephrinesforexclusionofpheochromocytomacanspecificitybeimprovedbyadjustmentforage
_version_ 1724599618744877056